Rhythm Pharmaceuticals, Inc.

As of June 30, 2026, Rhythm Pharmaceuticals, Inc. carries a market capitalization of 6.71B, placing it among publicly traded companies globally. Its enterprise value stands at 6.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Rhythm Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Rhythm Pharmaceuticals, Inc. has 68.82M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 31.30, and the price-to-book ratio stands at 74.43.

These figures are as of June 30, 2026. The EV/Sales ratio of 31.06 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 6.52B versus a market cap of 6.71B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Rhythm Pharmaceuticals, Inc. maintains a current ratio of 3.45, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.69, indicating elevated leverage, while an interest coverage ratio of -10.80 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -50.70, reflecting losses generated across the asset base. The company generates approximately 550,820.26 in revenue per employee across its workforce of 381.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.07 indicates how many times Rhythm Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Rhythm Pharmaceuticals, Inc. recorded 935,695.70 in income tax expense. The company reported a pretax loss of -178.80M and -179.74M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Rhythm Pharmaceuticals, Inc.'s stock has declined approximately 13.83% over the past 52 weeks. The 50-day moving average sits at 86.80, while the 200-day moving average is 84.36.

Over the twelve months ended June 30, 2026, Rhythm Pharmaceuticals, Inc. generated 210.00M in revenue and converted that into -179.74M in net income, yielding earnings per share of -2.67. EBITDA reached -174.67M, while operating income came in at -175.61M.

As of June 30, 2026, Rhythm Pharmaceuticals, Inc. holds 289.63M in cash and equivalents against 3.22M in total debt, resulting in a net debt position of -57.43M. Total book value stands at 90.14M, with working capital of 265.19M providing operational flexibility.

Rhythm Pharmaceuticals, Inc. produced -92.21M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Rhythm Pharmaceuticals, Inc. posted a gross margin of 89.00, reflecting its pricing power and cost economics. The operating margin of -83.62 and net profit margin of -85.59 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. The dividend payout ratio of 2.32 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.35, meaning Rhythm Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Rhythm Pharmaceuticals, Inc. has an Altman Z-Score of 16.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.